No. S 234
Misuse of Drugs Act
(CHAPTER 185)
Misuse of Drugs (Amendment)
Regulations 2018
In exercise of the powers conferred by section 58(1) of the Misuse of Drugs Act, the Minister for Home Affairs makes the following Regulations:
Citation and commencement
1.  These Regulations are the Misuse of Drugs (Amendment) Regulations 2018 and come into operation on 1 May 2018.
Amendment of Second Schedule
2.  The Second Schedule to the Misuse of Drugs Regulations (Rg 1) is amended —
(a)by deleting the item “Remifentanil” in paragraph 1;
(b)by deleting the item “3‑methylthiofentanyl” in paragraph 1;
(c)by deleting the full‑stop at the end of “4‑Phenylpiperidine‑4‑carboxylic acid ethyl ester” in paragraph 1, and by inserting immediately thereafter the following item:
 
“6,7,8,14-Tetradehydro-4,5-α-epoxy-6-methoxy-17-methylmorphinan-3-ol (also known as 3-O-demethylthebaine or Oripavine).”;
(d)by inserting, immediately after item (1) of paragraph 10, the following item:
“(1A)Acryloylfentanyl (also known as Acrylfentanyl)”;
(e)by inserting, immediately after item (9) of paragraph 10, the following items:
“(9A)4-Fluoroisobutyrfentanyl (also known as 4‑FIBF or pFIBF)
(9B)Furanyl fentanyl”;
(f)by inserting, immediately after item (11) of paragraph 10, the following items:
“(11A)3-Methylthiofentanyl
(11B)Ocfentanil”;
(g)by inserting, immediately after item (12) of paragraph 10, the following item:
“(12A)Remifentanil”; and
(h)by inserting, immediately after item (13) of paragraph 10, the following item:
“(13A)Tetrahydrofuranyl fentanyl (also known as THF-F)”.
Amendment of Fourth Schedule
3.  The Fourth Schedule to the Misuse of Drugs Regulations is amended —
(a)by inserting, immediately after item (1) of paragraph 15, the following item:
“(1AA)1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)-1-butanone (also known as Dibutylone or bk‑DMBDB)”;
(b)by inserting, immediately after item (1A) of paragraph 15, the following items:
“(1AB)1-(1,3-Benzodioxol-5-yl)‑2‑(ethylamino)‑1‑butanone (also known as Eutylone)
(1AC)1-(1,3-Benzodioxol-5-yl)‑2‑(ethylamino)pentan‑1-one (also known as N‑Ethylpentylone)”;
(c)by inserting, immediately after item (8A) of paragraph 15, the following item:
 
“(8AAA)1-(4-Bromophenyl)-2-(ethylamino)propan-1-one (also known as 4-Bromoethcathinone or 4-BEC)”;
(d)by inserting, immediately after item (8AA) of paragraph 15, the following item:
“(8AB)1-(4-Chlorophenyl)‑2‑(ethylamino)propan‑1‑one (also known as 4‑Chloroethcathinone or 4‑CEC)”;
(e)by inserting, immediately after item (10B) of paragraph 15, the following item:
“(10C)2-(Ethylamino)‑1‑(4‑methylphenyl)pentan‑1‑one (also known as 4‑Methyl‑α‑ethylaminopentiophenone or 4‑MEAPP)”;
(f)by inserting, immediately after item (12) of paragraph 15, the following item:
“(12A)2-(Ethylamino)‑1‑phenylhexan‑1‑one (also known as N‑Ethylhexedrone)”;
(g)by inserting, immediately after item (15) of paragraph 15, the following item:
“(15AA)1-(4-Fluorophenyl)‑2‑(pyrrolidin‑1‑yl)hexan‑1‑one (also known as 4‑Fluoro‑PHP)”;
(h)by inserting, immediately after item (1) of paragraph 17, the following item:
“(1AA)N-(1-Adamantyl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (also known as FUB‑APINACA or FUB‑AKB48) and its fluoro positional isomers in the phenyl ring”;
(i)by inserting, immediately after item (2B) of paragraph 17, the following item:
“(2BA)N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole‑3‑carboxamide (also known as ADB‑FUBINACA) and its fluoro positional isomers in the phenyl ring”;
(j)by inserting, immediately after item (2D) of paragraph 17, the following item:
“(2DA)N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide (also known as ADBICA)”;
(k)by deleting items (2E), (2F), (2G), (2H) and (2I) of paragraph 17 and substituting the following items:
“(2E)N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-chloropentyl)-1H-indazole-3-carboxamide (also known as 5-Chloro-AB-PINACA) and its N-(1-amino-1-oxopentan-2-yl) and N-(1-amino-2-methyl-1-oxobutan-2-yl) isomers and their respective chloro positional isomers in the pentyl group
(2F)N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as AB-CHMINACA) and its N-(1-amino-1-oxopentan-2-yl) and N-(1-amino-2-methyl-1-oxobutan-2-yl) isomers
(2G)N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (also known as AB-FUBINACA) and its N-(1-amino-1-oxopentan-2-yl) and N-(1-amino-2-methyl-1-oxobutan-2-yl) isomers and their respective fluoro positional isomers in the phenyl ring
(2H)N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (also known as 5-Fluoro-AB-PINACA) and its N-(1-amino-1-oxopentan-2-yl) and N-(1-amino-2-methyl-1-oxobutan-2-yl) isomers and their respective fluoro positional isomers in the pentyl group
(2I)N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (also known as AB-PINACA) and its N-(1-amino-1-oxopentan-2-yl) and N-(1-amino-2-methyl-1-oxobutan-2-yl) isomers
(2IA)N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as PX‑3 or APP‑CHMINACA)”;
(l)by deleting item (6B) of paragraph 17 and substituting the following items:
“(6B)1-Benzyl-4-methylpiperazine (also known as Methylbenzylpiperazine or MBZP)
(6C)2-Bis(4-fluorophenyl)methylsulfinyl-N-methylacetamide (also known as N-Methyl-4,4-difluoromodafinil or modafiendz) and its fluoro positional isomers in the phenyl rings
(6D)2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (also known as 25B-NBOMe) and its bromo, dimethoxy and methoxy positional isomers in the respective phenyl rings
(6E)2-N-[2-(4-Bromo-2,5-dimethoxyphenylethyl)aminomethyl]phenol (also known as 25B-NBOH) and its bromo, dimethoxy and hydroxy positional isomers in the respective phenyl rings”;
(m)by deleting item (8A) of paragraph 17 and substituting the following items:
“(8A)2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (also known as 2C‑C) and its chloro and dimethoxy positional isomers in the phenyl ring
(8AA)2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (also known as 25C‑NBOMe) and its chloro, dimethoxy and methoxy positional isomers in the respective phenyl rings
(8AB)2-N-[2-(4-Chloro-2,5-dimethoxyphenylethyl)aminomethyl]phenol (also known as 25C‑NBOH) and its chloro, dimethoxy and hydroxy positional isomers in the respective phenyl rings”;
(n)by deleting item (15A) of paragraph 17 and substituting the following item:
“(15A)2-(2,5-Dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (also known as 25H‑NBOMe) and its dimethoxy and methoxy positional isomers in the respective phenyl rings”;
(o)by inserting, immediately after item (15B) of paragraph 17, the following item:
“(15C)2-N-[2-(2,5-Dimethoxyphenylethyl)aminomethyl]phenol (also known as 25H‑NBOH) and its dimethoxy and hydroxy positional isomers in the respective phenyl rings”;
(p)by inserting, immediately after item (19) of paragraph 17, the following items:
“(19AA)Ethyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3, 3-dimethylbutanoate (also known as 5-Fluoro-EDMB-PINACA) and its hexanoate isomers and their respective fluoro positional isomers in the pentyl group
(19AB)4-Fluoromethylphenidate and its fluoro positional isomers in the phenyl ring”;
(q)by inserting, immediately after item (20A) of paragraph 17, the following items:
“(20B)2-[1-(5-Fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoic acid and its hexanoic acid isomers and their respective fluoro positional isomers in the pentyl group
(20C)2-[1-(5-Fluoropentyl)-1H-indole-3-carboxamido]-3,3-dimethylbutanoic acid and its hexanoic acid isomers and their respective fluoro positional isomers in the pentyl group”;
(r)by deleting item (27B) of paragraph 17 and substituting the following item:
“(27B)2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (also known as 25I‑NBOMe) and its dimethoxy, iodo and methoxy positional isomers in the respective phenyl rings”;
(s)by inserting, immediately after item (27C) of paragraph 17, the following items:
“(27D)2-N-[2-(4-Iodo-2,5-dimethoxyphenylethyl)aminomethyl]phenol (also known as 25I‑NBOH) and its dimethoxy, hydroxy and iodo positional isomers in the respective phenyl rings
(27E)3-Methoxy-2-(methylamino)-1-(4-methylphenyl)propan-1-one (also known as Mexedrone) and its methyl positional isomers in the phenyl ring”;
(t)by deleting item (28B) of paragraph 17 and substituting the following item:
“(28B)Methyl 2-[1-(cyclohexylmethyl)-1H-indazole-3-carboxamido]-3-methylbutanoate (also known as MA‑CHMINACA) and its 1‑pentanoate and 2‑methylbutanoate isomers”;
(u)by deleting item (28C) of paragraph 17 and substituting the following items:
“(28C)Methyl 2-[1-(cyclohexylmethyl)-1H-indole-3-carboxamido]-3-methylbutanoate (also known as MMB‑CHMICA) and its 1‑pentanoate and 2‑methylbutanoate isomers
(28D)Methyl 2-[1-(4-fluorobenzyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (also known as MDMB‑FUBINACA) and its fluoro positional isomers in the phenyl ring
(28E)Methyl 2-[1-(4-fluorobenzyl)-1H-indazole-3-carboxamido]-3-methylbutanoate (also known as MMB-FUBINACA) and its 1‑pentanoate and 2‑methylbutanoate isomers and their respective fluoro positional isomers in the phenyl ring
(28F)Methyl 2-[1-(4-fluorobenzyl)-1H-indole-3-carboxamido]-3-methylbutanoate (also known as MMB-FUBICA or AMB‑FUBICA) and its 1‑pentanoate and 2‑methylbutanoate isomers and their respective fluoro positional isomers in the phenyl ring
(28G)Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (also known as 5‑Fluoro‑MDMB‑PINACA or 5‑Fluoro‑ADB) and its hexanoate isomers and their respective fluoro positional isomers in the pentyl group
(28H)Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3-methylbutanoate (also known as 5‑Fluoro-AMB) and its 1‑pentanoate and 2‑methylbutanoate isomers and their respective fluoro positional isomers in the pentyl group
(28I)Methyl 2-[1-(5-fluoropentyl)-1H-indole-3-carboxamido]-3, 3-dimethylbutanoate (also known as 5‑Fluoro‑MDMB‑PICA) and its hexanoate isomers and their respective fluoro positional isomers in the pentyl group”;
(v)by inserting, immediately after item (29) of paragraph 17, the following item:
“(29A)Methyl 2-[1-(5-hydroxypentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate and its hexanoate isomers and their respective hydroxy positional isomers in the pentyl group”; and
(w)by inserting, immediately after item (31) of paragraph 17, the following item:
“(31A)N-(1-Methyl-1-phenylethyl)-1-(4-cyanobutyl)-1H-indazole-3-carboxamide (also known as Cumyl‑4CN‑BINACA or 4‑Cyano cumyl‑butinaca or SGT‑78) and its phenylpropyl isomers and their respective cyano positional isomers in the butyl group”.
[G.N. Nos. S 390/99; S 231/2000; S 436/2000; S 140/2001; S 492/2001; S 506/2005; S 490/2006; S 108/2007; S 525/2010; S 684/2010; S 270/2013; S 322/2014; S 571/2014; S 253/2015; S 199/2016; S 193/2017]
Made on 27 April 2018.
PANG KIN KEONG
Permanent Secretary,
Ministry of Home Affairs,
Singapore.
[MHA 112/2/0049; AG/LEGIS/SL/185/2015/2 Vol. 1]
Singapore Statutes Online
© 2024 Attorney-General's Chambers of Singapore,
Last updated 27 Nov 2024
Singapore Statutes Online is provided by the Legislation Division of the Attorney-General's Chambers of Singapore.